All filters
Slidesets
Model-based TDM for oncology drugs | Ron Keizer, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Physiologically based PK model vs. Population PK approach during drug development | Italo Poggesi, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Opening Lecture: Inter- and intravariability in PK | Mark Ratain, MD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Clinical case discussions | Nielka van Erp, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
PK and PKPD considerations for dose selection in the development of pembrolizumab | Dinesh de Alwis, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017